CJC-1295 and Ipamorelin are two of the most widely studied research peptides in the field of growth hormone (GH) research. Used individually or in combination, these compounds target distinct pituitary receptor systems to modulate GH secretion. This article examines their mechanisms, research applications, and the importance of sourcing from reliable peptides raw material manufacturers.
CJC-1295: The GHRH Analog
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the 44-amino-acid hypothalamic peptide that drives pulsatile GH secretion from the anterior pituitary. The modified form contains a drug affinity complex (DAC) technology that binds the peptide to serum albumin, extending its half-life from minutes to several days. A single CJC-1295 dose produced 2- to 10-fold GH elevation persisting 6 or more days, with IGF-1 rising 1.5- to 3-fold.
Ipamorelin: The Ghrelin Mimetic
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that acts at the ghrelin receptor (GHSR-1a). It was developed as a highly selective GH secretagogue, meaning it stimulates GH release without the clinically relevant cortisol, prolactin, or ACTH elevation observed with earlier GHS compounds.
The Combination Rationale
Pituitary somatotroph cells express both GHRH receptors and ghrelin receptors. Simultaneous activation of both receptor systems produces synergistic GH pulses, with CJC-1295 extending GH pulse amplitude and ipamorelin triggering GH pulse initiation.
Research Applications
CJC-1295 and ipamorelin are utilized in laboratory settings for:
– Growth hormone regulation and pulsatility studies.
– Muscle preservation and recovery research.
– Metabolic and body composition studies.
– Aging and gerontology research.
Research Findings
CJC-1295 combined with ipamorelin showed significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss. These findings, however, are limited to animal studies.
Regulatory Status
As of April 2026, both CJC-1295 and ipamorelin are on the FDA 503A Category 2 bulk substances list, meaning they cannot be legally compounded under Section 503A pending further FDA review. Neither compound is FDA-approved for any indication.
Sourcing Considerations
When sourcing these research peptides from peptide raw material suppliers, verify:
– HPLC Purity : ≥98% with batch-specific COA.
– Mass Confirmation : CJC-1295 (approximately 3,647 Da) and ipamorelin (approximately 711 Da).
– Endotoxin Testing : Essential for in-vivo studies.
Product Disclaimer & Terms of Use
IMPORTANT NOTICE: FOR RESEARCH USE ONLY (RUO)
This product is intended exclusively for laboratory research and scientific development purposes. It is NOT a drug, food, medical device, cosmetic, or diagnostic product.